drugset / Trial / NCT05759572
Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer
Phase 2
Active not recruiting
145 enrolled
Fudan University
Affiliated Hospital of Nantong University · collabChongqing University Cancer Hospital · collabFirst Affiliated Hospital Xi'an Jiaotong University · collabFirst Hospital of China Medical University · collabFujian Medical University Union Hospital · collabHebei Medical University Fourth Hospital · collabLiaoning Cancer Hospital & Institute · collabNingbo Medical Center Lihuili Hospital · collabNorthern Jiangsu People's Hospital · collabPeking University Cancer Hospital & Institute · collabShanghai First Maternity and Infant Hospital · collabSun Yat-Sen University Cancer Center · collabThe First Hospital of Jilin University · collabThe Third Affiliated Hospital of Nanchang University · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is a prospective, open-label, phase II clinical study for patients with HR+/HER2- advanced breast cancer.
Timeline
- Start
- 2023-03-01
- Primary completion
- 2026-07-21
- Completion
- 2027-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rivoceranib | Small molecule | — | — |
| Background | Dalpiciclib | Small molecule | — | — |
| Background | Fulvestrant | Small molecule | — | — |